Need to Know: Here are four reasons the West is headed for a ‘very drastic crisis,’ according to a veteran economist
The excess in financial markets will have to unwind in a drastic manner, warns one veteran economist.
MarketWatch
London Markets: Royal Dutch Shell stock gets a boost as oil prices trade around highest levels since 2018
Crude prices were trading at multiyear highs on Tuesday following the breakdown of output talks among the OPEC+ group of oil…
Blend Labs sets IPO terms, to be valued at up to nearly $4 billion
Blend Labs Inc. has set terms for its initial public offering, in which the California-based financial services software company…
: Is the market pricing in ‘peak growth’? These charts suggest as much, says a leading strategist.
The market is seemingly adopting the idea that growth won’t get any better than it currently is, according to David Rosenberg,…
Private-equity battle shapes up for number-four U.K. supermarket chain
A private-equity battle for a U.K. supermarket chain highlighted an otherwise quiet day in European stocks on Monday, with the…
Market Snapshot: What to expect if ‘peak everything’ already has happened and markets feel the force of gravity again
After a stunning first-half, the rest of 2021 could see the U.S. economy expand at a slower pace and inflation fall back to earth….
Millions of Americans still aren’t entering the labor market despite record job openings
With 850,000 new jobs added in June, there is not a short supply of work but many people are still not entering the labor market….
: Amazon’s incoming CEO Jassy gets $215 million in restricted stock
Amazon.com Inc. AMZN said late Friday its incoming chief executive, Andrew Jassy, will get an estimated eight-figure stock award…
The Margin: What is Bobby Bonilla Day? It is the beauty of compound interest
Bobby Bonilla was trending on Twitter Thursday morning because July 1 marks an annual payday for the former third baseman that…
FDA made a mistake in approving a questionable Alzheimer’s drug, but Medicare could act to reduce false hopes and unethical profits
The government should reimburse Biogen only for actual production costs while further clinical trials determine whether aducanumab…